世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
希少血友病因子の世界市場 2022-2026Global Rare Hemophilia Factors Market 2022-2026 希少血友病因子の世界市場 2022-2026 年 Technavioは希少血友病因子市場を監視しており、2022-2026年の間に1億4676万ドルの成長が見込まれ、予測期間中にCAGR7.4％で減速しています。当レポートでは、希少血友病... もっと見る
日本語のページは自動翻訳を利用し作成しています。 
サマリー希少血友病因子の世界市場 2022-2026 年Technavioは希少血友病因子市場を監視しており、2022-2026年の間に1億4676万ドルの成長が見込まれ、予測期間中にCAGR7.4％で減速しています。当レポートでは、希少血友病因子市場について、全体的な分析、市場規模と予測、動向、成長ドライバー、課題、さらに約25社のベンダーを網羅したベンダー分析などを提供しています。 現在の世界市場のシナリオ、最新動向とドライバー、市場全体の環境に関する最新の分析を提供しています。市場は、新しい治療技術の承認、費用対効果の高い高品質の医療ソリューションの導入、政府の有利な取り組みによって牽引されています。 希少血友病因子市場の分析には、手法セグメントと地理的展望が含まれます。 Technavioの希少血友病因子市場は、以下のように区分されています。 方法別 - 新鮮凍結血漿 - 因子濃縮物 - 凍結沈殿物 - その他 地域別状況 - 北アメリカ - 欧州 - アジア - その他の地域（ROW） 本調査では、遺伝子治療の登場が、今後数年間の希少血友病因子市場の成長を促進する主要な理由の1つであると特定しています。また、治療薬を開発するための技術革新と新規戦略の研究開発の増加が、市場の大きな需要につながると考えられます。 Technavio社は、複数のソースからのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。希少血友病因子市場に関する当レポートの対象領域は以下の通りです。 - 希少血友病因子市場のサイジング - 希少血友病因子市場の予測 - 希少血友病因子市場の産業分析 Technavioの強力なベンダー分析は、顧客が市場での地位を向上できるように設計されており、これに沿って、本レポートでは、Alnylam Pharmaceuticals Inc.を含むいくつかの主要な希少血友病因子市場のベンダーについて詳細な分析を提供します。Aptevo Therapeutics Inc.、Bayer AG、Bio Products Laboratory Ltd.、Catalyst Biosciences, Inc.、CSL Ltd.、F. Hoffmann La Roche Ltd.、Genentech Inc、Grifols SA、Kedrion Spa、Novo Nordisk、Octapharma AG、Pfizer Inc、Sanofi SA、Takeda Pharmaceutical Co.Ltd.、The Johns Hopkins Health System Corp.、UCSF Health、uniQure NV、Versiti、Intermountain Healthcareの6社が含まれています。また、希少血友病因子市場の分析レポートには、今後の動向や市場成長に影響を与える課題に関する情報も含まれています。これは、企業が今後訪れるすべての成長機会を戦略化し、活用するのに役立つものです。 本調査は、業界の主要参加者からのインプットを含む一次情報および二次情報の客観的な組み合わせを使用して実施されました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/rare-hemophilia-factors-market-industry-analysis をご覧ください。 Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数のソースからのデータの研究、合成、総括の方法により、市場の詳細なイメージを提示します。また、業界の主要なインフルエンサーを特定することにより、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果である。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、定性的および定量的調査を用いた詳細なベンダー選定方法および分析を提供します。 目次• 1 Executive Summaryo 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market Segmentation by Method o Exhibit 05: Executive Summary - Data Table on Incremental Growth o Exhibit 06: Executive Summary - Chart on Vendor Market Positioning • 2 Market Landscape o 2.1 Market ecosystem o Exhibit 07: Parent market o Exhibit 08: Market Characteristics • 3 Market Sizing o 3.1 Market definition o Exhibit 09: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 10: Market segments o 3.3 Market size 2021 o 3.4 Market outlook: Forecast for 2021-2026 o Exhibit 11: Chart on Global - Market size and forecast 2021-2026 ($ million) o Exhibit 12: Data Table on Global - Market size and forecast 2021-2026 ($ million) o Exhibit 13: Chart on Global Market: Year-over-year growth 2021-2026 (%) o Exhibit 14: Data Table on Global Market: Year-over-year growth 2021-2026 (%) • 4 Five Forces Analysis o 4.1 Five forces summary o Exhibit 15: Five forces analysis - Comparison between 2021 and 2026 o 4.2 Bargaining power of buyers o Exhibit 16: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026 o 4.3 Bargaining power of suppliers o Exhibit 17: Bargaining power of suppliers - Impact of key factors in 2021 and 2026 o 4.4 Threat of new entrants o Exhibit 18: Threat of new entrants - Impact of key factors in 2021 and 2026 o 4.5 Threat of substitutes o Exhibit 19: Threat of substitutes - Impact of key factors in 2021 and 2026 o 4.6 Threat of rivalry o Exhibit 20: Threat of rivalry - Impact of key factors in 2021 and 2026 o 4.7 Market condition o Exhibit 21: Chart on Market condition - Five forces 2021 and 2026 • 5 Market Segmentation by Method o 5.1 Market segments o Exhibit 22: Chart on Method - Market share 2021-2026 (%) o Exhibit 23: Data Table on Method - Market share 2021-2026 (%) o 5.2 Comparison by Method o Exhibit 24: Chart on Comparison by Method o Exhibit 25: Data Table on Comparison by Method o 5.3 Fresh frozen plasma - Market size and forecast 2021-2026 o Exhibit 26: Chart on Fresh frozen plasma - Market size and forecast 2021-2026 ($ million) o Exhibit 27: Data Table on Fresh frozen plasma - Market size and forecast 2021-2026 ($ million) o Exhibit 28: Chart on Fresh frozen plasma - Year-over-year growth 2021-2026 (%) o Exhibit 29: Data Table on Fresh frozen plasma - Year-over-year growth 2021-2026 (%) o 5.4 Factor concentrates - Market size and forecast 2021-2026 o Exhibit 30: Chart on Factor concentrates - Market size and forecast 2021-2026 ($ million) o Exhibit 31: Data Table on Factor concentrates - Market size and forecast 2021-2026 ($ million) o Exhibit 32: Chart on Factor concentrates - Year-over-year growth 2021-2026 (%) o Exhibit 33: Data Table on Factor concentrates - Year-over-year growth 2021-2026 (%) o 5.5 Cryoprecipitate - Market size and forecast 2021-2026 o Exhibit 34: Chart on Cryoprecipitate - Market size and forecast 2021-2026 ($ million) o Exhibit 35: Data Table on Cryoprecipitate - Market size and forecast 2021-2026 ($ million) o Exhibit 36: Chart on Cryoprecipitate - Year-over-year growth 2021-2026 (%) o Exhibit 37: Data Table on Cryoprecipitate - Year-over-year growth 2021-2026 (%) o 5.6 Others - Market size and forecast 2021-2026 o Exhibit 38: Chart on Others - Market size and forecast 2021-2026 ($ million) o Exhibit 39: Data Table on Others - Market size and forecast 2021-2026 ($ million) o Exhibit 40: Chart on Others - Year-over-year growth 2021-2026 (%) o Exhibit 41: Data Table on Others - Year-over-year growth 2021-2026 (%) o 5.7 Market opportunity by Method o Exhibit 42: Market opportunity by Method ($ million) • 6 Customer Landscape o 6.1 Customer landscape overview o Exhibit 43: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria • 7 Drivers, Challenges, and Trends o 7.1 Market drivers o 7.2 Market challenges o 7.3 Impact of drivers and challenges o Exhibit 44: Impact of drivers and challenges in 2021 and 2026 o 7.4 Market trends • 8 Vendor Landscape o 8.1 Overview o 8.2 Vendor landscape o Exhibit 45: Overview on Criticality of inputs and Factors of differentiation o 8.3 Landscape disruption o Exhibit 46: Overview on factors of disruption o 8.4 Industry risks o Exhibit 47: Impact of key risks on business • 9 Vendor Analysis o 9.1 Vendors covered o Exhibit 48: Vendors covered o 9.2 Market positioning of vendors o Exhibit 49: Matrix on vendor position and classification o 9.3 Aptevo Therapeutics Inc. o Exhibit 50: Aptevo Therapeutics Inc. - Overview o Exhibit 51: Aptevo Therapeutics Inc. - Product / Service o Exhibit 52: Aptevo Therapeutics Inc. - Key offerings o 9.4 Bayer AG o Exhibit 53: Bayer AG - Overview o Exhibit 54: Bayer AG - Business segments o Exhibit 55: Bayer AG - Key news o Exhibit 56: Bayer AG - Key offerings o Exhibit 57: Bayer AG - Segment focus o 9.5 CSL Ltd. o Exhibit 58: CSL Ltd. - Overview o Exhibit 59: CSL Ltd. - Business segments o Exhibit 60: CSL Ltd. - Key offerings o Exhibit 61: CSL Ltd. - Segment focus o 9.6 F. Hoffmann La Roche Ltd. o Exhibit 62: F. Hoffmann La Roche Ltd. - Overview o Exhibit 63: F. Hoffmann La Roche Ltd. - Business segments o Exhibit 64: F. Hoffmann La Roche Ltd. - Key news o Exhibit 65: F. Hoffmann La Roche Ltd. - Key offerings o Exhibit 66: F. Hoffmann La Roche Ltd. - Segment focus o 9.7 Grifols SA o Exhibit 67: Grifols SA - Overview o Exhibit 68: Grifols SA - Business segments o Exhibit 69: Grifols SA - Key offerings o Exhibit 70: Grifols SA - Segment focus o 9.8 Novo Nordisk o Exhibit 71: Novo Nordisk - Overview o Exhibit 72: Novo Nordisk - Business segments o Exhibit 73: Novo Nordisk - Key offerings o Exhibit 74: Novo Nordisk - Segment focus o 9.9 Octapharma AG o Exhibit 75: Octapharma AG - Overview o Exhibit 76: Octapharma AG - Product / Service o Exhibit 77: Octapharma AG - Key offerings o 9.10 Pfizer Inc. o Exhibit 78: Pfizer Inc. - Overview o Exhibit 79: Pfizer Inc. - Product / Service o Exhibit 80: Pfizer Inc. - Key news o Exhibit 81: Pfizer Inc. - Key offerings o 9.11 Sanofi o Exhibit 82: Sanofi - Overview o Exhibit 83: Sanofi - Business segments o Exhibit 84: Sanofi - Key news o Exhibit 85: Sanofi - Key offerings o Exhibit 86: Sanofi - Segment focus o 9.12 Takeda Pharmaceutical Co. Ltd. o Exhibit 87: Takeda Pharmaceutical Co. Ltd. - Overview o Exhibit 88: Takeda Pharmaceutical Co. Ltd. - Product / Service o Exhibit 89: Takeda Pharmaceutical Co. Ltd. - Key news o Exhibit 90: Takeda Pharmaceutical Co. Ltd. - Key offerings • 10 Appendix o 10.1 Scope of the report o 10.2 Inclusions and exclusions checklist o Exhibit 91: Inclusions checklist o Exhibit 92: Exclusions checklist o 10.3 Currency conversion rates for US$ o Exhibit 93: Currency conversion rates for US$ o 10.4 Research methodology o Exhibit 94: Research methodology o Exhibit 95: Validation techniques employed for market sizing o Exhibit 96: Information sources o 10.5 List of abbreviations o Exhibit 97: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market Segmentation by Method Exhibits5: Executive Summary - Data Table on Incremental Growth Exhibits6: Executive Summary - Chart on Vendor Market Positioning Exhibits7: Parent market Exhibits8: Market Characteristics Exhibits9: Offerings of vendors included in the market definition Exhibits10: Market segments Exhibits11: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibits12: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibits13: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibits14: Data Table on Global Market: Year-over-year growth 2021-2026 (%) Exhibits15: Five forces analysis - Comparison between 2021 and 2026 Exhibits16: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026 Exhibits17: Bargaining power of suppliers - Impact of key factors in 2021 and 2026 Exhibits18: Threat of new entrants - Impact of key factors in 2021 and 2026 Exhibits19: Threat of substitutes - Impact of key factors in 2021 and 2026 Exhibits20: Threat of rivalry - Impact of key factors in 2021 and 2026 Exhibits21: Chart on Market condition - Five forces 2021 and 2026 Exhibits22: Chart on Method - Market share 2021-2026 (%) Exhibits23: Data Table on Method - Market share 2021-2026 (%) Exhibits24: Chart on Comparison by Method Exhibits25: Data Table on Comparison by Method Exhibits26: Chart on Fresh frozen plasma - Market size and forecast 2021-2026 ($ million) Exhibits27: Data Table on Fresh frozen plasma - Market size and forecast 2021-2026 ($ million) Exhibits28: Chart on Fresh frozen plasma - Year-over-year growth 2021-2026 (%) Exhibits29: Data Table on Fresh frozen plasma - Year-over-year growth 2021-2026 (%) Exhibits30: Chart on Factor concentrates - Market size and forecast 2021-2026 ($ million) Exhibits31: Data Table on Factor concentrates - Market size and forecast 2021-2026 ($ million) Exhibits32: Chart on Factor concentrates - Year-over-year growth 2021-2026 (%) Exhibits33: Data Table on Factor concentrates - Year-over-year growth 2021-2026 (%) Exhibits34: Chart on Cryoprecipitate - Market size and forecast 2021-2026 ($ million) Exhibits35: Data Table on Cryoprecipitate - Market size and forecast 2021-2026 ($ million) Exhibits36: Chart on Cryoprecipitate - Year-over-year growth 2021-2026 (%) Exhibits37: Data Table on Cryoprecipitate - Year-over-year growth 2021-2026 (%) Exhibits38: Chart on Others - Market size and forecast 2021-2026 ($ million) Exhibits39: Data Table on Others - Market size and forecast 2021-2026 ($ million) Exhibits40: Chart on Others - Year-over-year growth 2021-2026 (%) Exhibits41: Data Table on Others - Year-over-year growth 2021-2026 (%) Exhibits42: Market opportunity by Method ($ million) Exhibits43: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits44: Impact of drivers and challenges in 2021 and 2026 Exhibits45: Overview on Criticality of inputs and Factors of differentiation Exhibits46: Overview on factors of disruption Exhibits47: Impact of key risks on business Exhibits48: Vendors covered Exhibits49: Matrix on vendor position and classification Exhibits50: Aptevo Therapeutics Inc. - Overview Exhibits51: Aptevo Therapeutics Inc. - Product / Service Exhibits52: Aptevo Therapeutics Inc. - Key offerings Exhibits53: Bayer AG - Overview Exhibits54: Bayer AG - Business segments Exhibits55: Bayer AG - Key news Exhibits56: Bayer AG - Key offerings Exhibits57: Bayer AG - Segment focus Exhibits58: CSL Ltd. - Overview Exhibits59: CSL Ltd. - Business segments Exhibits60: CSL Ltd. - Key offerings Exhibits61: CSL Ltd. - Segment focus Exhibits62: F. Hoffmann La Roche Ltd. - Overview Exhibits63: F. Hoffmann La Roche Ltd. - Business segments Exhibits64: F. Hoffmann La Roche Ltd. - Key news Exhibits65: F. Hoffmann La Roche Ltd. - Key offerings Exhibits66: F. Hoffmann La Roche Ltd. - Segment focus Exhibits67: Grifols SA - Overview Exhibits68: Grifols SA - Business segments Exhibits69: Grifols SA - Key offerings Exhibits70: Grifols SA - Segment focus Exhibits71: Novo Nordisk - Overview Exhibits72: Novo Nordisk - Business segments Exhibits73: Novo Nordisk - Key offerings Exhibits74: Novo Nordisk - Segment focus Exhibits75: Octapharma AG - Overview Exhibits76: Octapharma AG - Product / Service Exhibits77: Octapharma AG - Key offerings Exhibits78: Pfizer Inc. - Overview Exhibits79: Pfizer Inc. - Product / Service Exhibits80: Pfizer Inc. - Key news Exhibits81: Pfizer Inc. - Key offerings Exhibits82: Sanofi - Overview Exhibits83: Sanofi - Business segments Exhibits84: Sanofi - Key news Exhibits85: Sanofi - Key offerings Exhibits86: Sanofi - Segment focus Exhibits87: Takeda Pharmaceutical Co. Ltd. - Overview Exhibits88: Takeda Pharmaceutical Co. Ltd. - Product / Service Exhibits89: Takeda Pharmaceutical Co. Ltd. - Key news Exhibits90: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibits91: Inclusions checklist Exhibits92: Exclusions checklist Exhibits93: Currency conversion rates for US$ Exhibits94: Research methodology Exhibits95: Validation techniques employed for market sizing Exhibits96: Information sources Exhibits97: List of abbreviations
SummaryGlobal Rare Hemophilia Factors Market 2022-2026 Table of Contents• 1 Executive Summaryo 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market Segmentation by Method o Exhibit 05: Executive Summary - Data Table on Incremental Growth o Exhibit 06: Executive Summary - Chart on Vendor Market Positioning • 2 Market Landscape o 2.1 Market ecosystem o Exhibit 07: Parent market o Exhibit 08: Market Characteristics • 3 Market Sizing o 3.1 Market definition o Exhibit 09: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 10: Market segments o 3.3 Market size 2021 o 3.4 Market outlook: Forecast for 2021-2026 o Exhibit 11: Chart on Global - Market size and forecast 2021-2026 ($ million) o Exhibit 12: Data Table on Global - Market size and forecast 2021-2026 ($ million) o Exhibit 13: Chart on Global Market: Year-over-year growth 2021-2026 (%) o Exhibit 14: Data Table on Global Market: Year-over-year growth 2021-2026 (%) • 4 Five Forces Analysis o 4.1 Five forces summary o Exhibit 15: Five forces analysis - Comparison between 2021 and 2026 o 4.2 Bargaining power of buyers o Exhibit 16: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026 o 4.3 Bargaining power of suppliers o Exhibit 17: Bargaining power of suppliers - Impact of key factors in 2021 and 2026 o 4.4 Threat of new entrants o Exhibit 18: Threat of new entrants - Impact of key factors in 2021 and 2026 o 4.5 Threat of substitutes o Exhibit 19: Threat of substitutes - Impact of key factors in 2021 and 2026 o 4.6 Threat of rivalry o Exhibit 20: Threat of rivalry - Impact of key factors in 2021 and 2026 o 4.7 Market condition o Exhibit 21: Chart on Market condition - Five forces 2021 and 2026 • 5 Market Segmentation by Method o 5.1 Market segments o Exhibit 22: Chart on Method - Market share 2021-2026 (%) o Exhibit 23: Data Table on Method - Market share 2021-2026 (%) o 5.2 Comparison by Method o Exhibit 24: Chart on Comparison by Method o Exhibit 25: Data Table on Comparison by Method o 5.3 Fresh frozen plasma - Market size and forecast 2021-2026 o Exhibit 26: Chart on Fresh frozen plasma - Market size and forecast 2021-2026 ($ million) o Exhibit 27: Data Table on Fresh frozen plasma - Market size and forecast 2021-2026 ($ million) o Exhibit 28: Chart on Fresh frozen plasma - Year-over-year growth 2021-2026 (%) o Exhibit 29: Data Table on Fresh frozen plasma - Year-over-year growth 2021-2026 (%) o 5.4 Factor concentrates - Market size and forecast 2021-2026 o Exhibit 30: Chart on Factor concentrates - Market size and forecast 2021-2026 ($ million) o Exhibit 31: Data Table on Factor concentrates - Market size and forecast 2021-2026 ($ million) o Exhibit 32: Chart on Factor concentrates - Year-over-year growth 2021-2026 (%) o Exhibit 33: Data Table on Factor concentrates - Year-over-year growth 2021-2026 (%) o 5.5 Cryoprecipitate - Market size and forecast 2021-2026 o Exhibit 34: Chart on Cryoprecipitate - Market size and forecast 2021-2026 ($ million) o Exhibit 35: Data Table on Cryoprecipitate - Market size and forecast 2021-2026 ($ million) o Exhibit 36: Chart on Cryoprecipitate - Year-over-year growth 2021-2026 (%) o Exhibit 37: Data Table on Cryoprecipitate - Year-over-year growth 2021-2026 (%) o 5.6 Others - Market size and forecast 2021-2026 o Exhibit 38: Chart on Others - Market size and forecast 2021-2026 ($ million) o Exhibit 39: Data Table on Others - Market size and forecast 2021-2026 ($ million) o Exhibit 40: Chart on Others - Year-over-year growth 2021-2026 (%) o Exhibit 41: Data Table on Others - Year-over-year growth 2021-2026 (%) o 5.7 Market opportunity by Method o Exhibit 42: Market opportunity by Method ($ million) • 6 Customer Landscape o 6.1 Customer landscape overview o Exhibit 43: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria • 7 Drivers, Challenges, and Trends o 7.1 Market drivers o 7.2 Market challenges o 7.3 Impact of drivers and challenges o Exhibit 44: Impact of drivers and challenges in 2021 and 2026 o 7.4 Market trends • 8 Vendor Landscape o 8.1 Overview o 8.2 Vendor landscape o Exhibit 45: Overview on Criticality of inputs and Factors of differentiation o 8.3 Landscape disruption o Exhibit 46: Overview on factors of disruption o 8.4 Industry risks o Exhibit 47: Impact of key risks on business • 9 Vendor Analysis o 9.1 Vendors covered o Exhibit 48: Vendors covered o 9.2 Market positioning of vendors o Exhibit 49: Matrix on vendor position and classification o 9.3 Aptevo Therapeutics Inc. o Exhibit 50: Aptevo Therapeutics Inc. - Overview o Exhibit 51: Aptevo Therapeutics Inc. - Product / Service o Exhibit 52: Aptevo Therapeutics Inc. - Key offerings o 9.4 Bayer AG o Exhibit 53: Bayer AG - Overview o Exhibit 54: Bayer AG - Business segments o Exhibit 55: Bayer AG - Key news o Exhibit 56: Bayer AG - Key offerings o Exhibit 57: Bayer AG - Segment focus o 9.5 CSL Ltd. o Exhibit 58: CSL Ltd. - Overview o Exhibit 59: CSL Ltd. - Business segments o Exhibit 60: CSL Ltd. - Key offerings o Exhibit 61: CSL Ltd. - Segment focus o 9.6 F. Hoffmann La Roche Ltd. o Exhibit 62: F. Hoffmann La Roche Ltd. - Overview o Exhibit 63: F. Hoffmann La Roche Ltd. - Business segments o Exhibit 64: F. Hoffmann La Roche Ltd. - Key news o Exhibit 65: F. Hoffmann La Roche Ltd. - Key offerings o Exhibit 66: F. Hoffmann La Roche Ltd. - Segment focus o 9.7 Grifols SA o Exhibit 67: Grifols SA - Overview o Exhibit 68: Grifols SA - Business segments o Exhibit 69: Grifols SA - Key offerings o Exhibit 70: Grifols SA - Segment focus o 9.8 Novo Nordisk o Exhibit 71: Novo Nordisk - Overview o Exhibit 72: Novo Nordisk - Business segments o Exhibit 73: Novo Nordisk - Key offerings o Exhibit 74: Novo Nordisk - Segment focus o 9.9 Octapharma AG o Exhibit 75: Octapharma AG - Overview o Exhibit 76: Octapharma AG - Product / Service o Exhibit 77: Octapharma AG - Key offerings o 9.10 Pfizer Inc. o Exhibit 78: Pfizer Inc. - Overview o Exhibit 79: Pfizer Inc. - Product / Service o Exhibit 80: Pfizer Inc. - Key news o Exhibit 81: Pfizer Inc. - Key offerings o 9.11 Sanofi o Exhibit 82: Sanofi - Overview o Exhibit 83: Sanofi - Business segments o Exhibit 84: Sanofi - Key news o Exhibit 85: Sanofi - Key offerings o Exhibit 86: Sanofi - Segment focus o 9.12 Takeda Pharmaceutical Co. Ltd. o Exhibit 87: Takeda Pharmaceutical Co. Ltd. - Overview o Exhibit 88: Takeda Pharmaceutical Co. Ltd. - Product / Service o Exhibit 89: Takeda Pharmaceutical Co. Ltd. - Key news o Exhibit 90: Takeda Pharmaceutical Co. Ltd. - Key offerings • 10 Appendix o 10.1 Scope of the report o 10.2 Inclusions and exclusions checklist o Exhibit 91: Inclusions checklist o Exhibit 92: Exclusions checklist o 10.3 Currency conversion rates for US$ o Exhibit 93: Currency conversion rates for US$ o 10.4 Research methodology o Exhibit 94: Research methodology o Exhibit 95: Validation techniques employed for market sizing o Exhibit 96: Information sources o 10.5 List of abbreviations o Exhibit 97: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market Segmentation by Method Exhibits5: Executive Summary - Data Table on Incremental Growth Exhibits6: Executive Summary - Chart on Vendor Market Positioning Exhibits7: Parent market Exhibits8: Market Characteristics Exhibits9: Offerings of vendors included in the market definition Exhibits10: Market segments Exhibits11: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibits12: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibits13: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibits14: Data Table on Global Market: Year-over-year growth 2021-2026 (%) Exhibits15: Five forces analysis - Comparison between 2021 and 2026 Exhibits16: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026 Exhibits17: Bargaining power of suppliers - Impact of key factors in 2021 and 2026 Exhibits18: Threat of new entrants - Impact of key factors in 2021 and 2026 Exhibits19: Threat of substitutes - Impact of key factors in 2021 and 2026 Exhibits20: Threat of rivalry - Impact of key factors in 2021 and 2026 Exhibits21: Chart on Market condition - Five forces 2021 and 2026 Exhibits22: Chart on Method - Market share 2021-2026 (%) Exhibits23: Data Table on Method - Market share 2021-2026 (%) Exhibits24: Chart on Comparison by Method Exhibits25: Data Table on Comparison by Method Exhibits26: Chart on Fresh frozen plasma - Market size and forecast 2021-2026 ($ million) Exhibits27: Data Table on Fresh frozen plasma - Market size and forecast 2021-2026 ($ million) Exhibits28: Chart on Fresh frozen plasma - Year-over-year growth 2021-2026 (%) Exhibits29: Data Table on Fresh frozen plasma - Year-over-year growth 2021-2026 (%) Exhibits30: Chart on Factor concentrates - Market size and forecast 2021-2026 ($ million) Exhibits31: Data Table on Factor concentrates - Market size and forecast 2021-2026 ($ million) Exhibits32: Chart on Factor concentrates - Year-over-year growth 2021-2026 (%) Exhibits33: Data Table on Factor concentrates - Year-over-year growth 2021-2026 (%) Exhibits34: Chart on Cryoprecipitate - Market size and forecast 2021-2026 ($ million) Exhibits35: Data Table on Cryoprecipitate - Market size and forecast 2021-2026 ($ million) Exhibits36: Chart on Cryoprecipitate - Year-over-year growth 2021-2026 (%) Exhibits37: Data Table on Cryoprecipitate - Year-over-year growth 2021-2026 (%) Exhibits38: Chart on Others - Market size and forecast 2021-2026 ($ million) Exhibits39: Data Table on Others - Market size and forecast 2021-2026 ($ million) Exhibits40: Chart on Others - Year-over-year growth 2021-2026 (%) Exhibits41: Data Table on Others - Year-over-year growth 2021-2026 (%) Exhibits42: Market opportunity by Method ($ million) Exhibits43: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits44: Impact of drivers and challenges in 2021 and 2026 Exhibits45: Overview on Criticality of inputs and Factors of differentiation Exhibits46: Overview on factors of disruption Exhibits47: Impact of key risks on business Exhibits48: Vendors covered Exhibits49: Matrix on vendor position and classification Exhibits50: Aptevo Therapeutics Inc. - Overview Exhibits51: Aptevo Therapeutics Inc. - Product / Service Exhibits52: Aptevo Therapeutics Inc. - Key offerings Exhibits53: Bayer AG - Overview Exhibits54: Bayer AG - Business segments Exhibits55: Bayer AG - Key news Exhibits56: Bayer AG - Key offerings Exhibits57: Bayer AG - Segment focus Exhibits58: CSL Ltd. - Overview Exhibits59: CSL Ltd. - Business segments Exhibits60: CSL Ltd. - Key offerings Exhibits61: CSL Ltd. - Segment focus Exhibits62: F. Hoffmann La Roche Ltd. - Overview Exhibits63: F. Hoffmann La Roche Ltd. - Business segments Exhibits64: F. Hoffmann La Roche Ltd. - Key news Exhibits65: F. Hoffmann La Roche Ltd. - Key offerings Exhibits66: F. Hoffmann La Roche Ltd. - Segment focus Exhibits67: Grifols SA - Overview Exhibits68: Grifols SA - Business segments Exhibits69: Grifols SA - Key offerings Exhibits70: Grifols SA - Segment focus Exhibits71: Novo Nordisk - Overview Exhibits72: Novo Nordisk - Business segments Exhibits73: Novo Nordisk - Key offerings Exhibits74: Novo Nordisk - Segment focus Exhibits75: Octapharma AG - Overview Exhibits76: Octapharma AG - Product / Service Exhibits77: Octapharma AG - Key offerings Exhibits78: Pfizer Inc. - Overview Exhibits79: Pfizer Inc. - Product / Service Exhibits80: Pfizer Inc. - Key news Exhibits81: Pfizer Inc. - Key offerings Exhibits82: Sanofi - Overview Exhibits83: Sanofi - Business segments Exhibits84: Sanofi - Key news Exhibits85: Sanofi - Key offerings Exhibits86: Sanofi - Segment focus Exhibits87: Takeda Pharmaceutical Co. Ltd. - Overview Exhibits88: Takeda Pharmaceutical Co. Ltd. - Product / Service Exhibits89: Takeda Pharmaceutical Co. Ltd. - Key news Exhibits90: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibits91: Inclusions checklist Exhibits92: Exclusions checklist Exhibits93: Currency conversion rates for US$ Exhibits94: Research methodology Exhibits95: Validation techniques employed for market sizing Exhibits96: Information sources Exhibits97: List of abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（その他）の最新刊レポート
TechNavio 社の最新刊レポート本レポートと同じKEY WORD（hemophilia）の最新刊レポート
よくあるご質問TechNavio社はどのような調査会社ですか?テクナビオ(TechNavio)は英国ロンドンに本社をおく幅広い市場を調査対象とする調査会社インフィニティリサーチ社(Infiniti Research)の調査レポート出版部門です。データリソースはT... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/08 10:26 154.13 円 166.76 円 202.76 円 |
